We are pleased to announce that PHERGain study “Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy” has achieved 40% of recruitment!!
The study assesses the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymph nodes and their predictive value for a pathologic complete response (pCR) in the breast and axilla.
58 sites are planned to participate in the study and a total of 295 patients have been recruited (160 patients randomized and 116 screening failure) since June 2017. It’s a very interesting study that involves collaboration from Oncology, Radiology and Pathological Anatomy services. Thank you very much to all of them and specially to Hospital Virgen del Rocío (Dr Manuel Ruiz Borrego), Hospital Clínic Universitari de Valencia (Dr Begoña Bermejo), Hospital Vall Hebrón (Dr Santiago Escribà), Hospital Ramón y Cajal (Dra Noelia Martinez) and ICO L’Hospitalet (Dra Agostina Stradella) as top recruiters. The research team was supported by an unrestricted fellowship from Roche.
We will continue working on study recruitment and we count with your collaboration to finalize patient inclusion in December 2018 with 400 patients enrolled.